Skip to Content

Vanderbilt-Ingram Cancer CenterVanderbilt-Ingram Cancer Center

 

Learn More

VICC toll-free number 1-877-936-8422

Clinical Trial VICCGI13114

Title

A Two Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination with Weekly Paclitaxel; Arm A: A Dose-Escalation Study in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors; Arm B: An Expansion Cohort in Patients with Relapsed or Refractory Esophageal Cancer or Gastro-esophageal Junction Tumors

Principal Investigator(s)

Emily Chan

Details

  • Protocol No. VICCGI13114
  • Open Date: 08/04/2014
  • Staging: Phase I
  • Age Group: Adults
  • Scope: National
  • Objective: To characterize the safety and tolerability of DKN-01 in combination with weekly paclitaxel in patients with refractory/recurrent esophageal or gastro-esophageal junction cancer
  • Disease Sites: Phase I; Esophageal; Gastric/Gastroesophageal
  • Therapies: Molecular Targeted Agents / Immunotherapy / Biologics
  • Drugs: DKN-01; Paclitaxel
  • Participating Institutions: Vanderbilt University
  • Secondary Protocol No: DEK-Dkk1-P102

Description

None Provided.

Eligibility

Not provided. Please call for more information.